I'm Not Average: Matt May Have Cancer, but Cancer Doesn’t Have Him

Holly Campbell   |     October 30, 2014   |   SHARE THIS

Screen_Shot_2015-02-26_at_11.00.19_AMWhen Matt Ellefson developed a cough, he didn’t think much of it.  He just assumed it was caused by the cold winter air, but as the weeks passed by his cough lingered.

Then he began coughing up blood.

Within hours of going to the ER, Matt was diagnosed with advanced non-small cell lung cancer, and the prognosis wasn’t good. With treatment, he faced a five-year survival rate of less than five percent.

His diagnosis in December 2009 was a complete shock. He was a non-smoker and lived a healthy and fit lifestyle. Soon after being diagnosed, Matt enrolled in an aggressive clinical trial. After five months, his cancer went into remission.

One year later his cancer resurfaced and it had spread. Treatment options were extremely slim. While waiting for his doctor for follow-up testing, he learned about a targeted gene therapy that was recently approved. However, the odds were still against him. Patients typically developed resistance to the medicine in eight months.

Three years later, Matt is living an active, happy life controlling his disease thanks to advances and innovations in cancer medicines. He runs marathons, participates in cycling competitions, and explores the world with his family. If he does become resistant to his current medicine, there have been three new drugs approved, so now he has other options.

He has hope because of the progress made in cancer research.

Matt’s story is part of PhRMA’s new campaign, I’m Not Average, to share inspirational stories from individuals about the powerful impact advances and innovations in cancer medicines have had on their lives.

For more information on the I’m Not Average campaign, please visit www.phrma.org/cancer.

Join the conversation about advances and innovations in cancer medicines using the hashtag #NotAverage.

Holly Campbell

Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Topics: Medicines in Development, Cancer, Patients, I'm Not Average

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates